Drug Profile
Baclofen extended release - Amneal Pharmaceuticals
Alternative Names: IPX 056Latest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator IMPAX Laboratories
- Developer Impax Pharmaceuticals
- Class Aminobutyric acids; Antispastics; Muscle relaxants; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Muscle spasticity
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 31 Dec 2012 No development reported - Phase-III for Spasticity in Canada (PO)
- 31 Dec 2012 No development reported - Phase-III for Spasticity in Estonia (PO)